Treatment groups | Rituximab monotherapy | Rituximab + MTX | Abatacept (n = 17) | Tocilizumab (n = 16) | MTX | Controls |
---|---|---|---|---|---|---|
(n = 85) | (n = 86) | |||||
(n = 29) | (n = 26) | |||||
Female gender, % | 72% | 62% | 88% | 81% | 79% | 45% |
Age, years, mean (SD) (range) | 68.9 (9) (50 to 87) | 59.9 (12) (39 to 85) | 56.6 (13) (29 to 75) | 55.6 (12) (27 to 72) | 61.5 (14) (24 to 85) | 51.6 (12) (22 to 75) |
Disease duration, years mean (SD) (range) | 21.3 (14) (0 to 57) | 14.5 (12) (2 to 50) | 14.9 (2.9) (2 to 46) | 13.8 (12) (0 to 43) | 11.4 (10) (0 to 40) | 12.7 (12) (0 to 45) |
HAQ, 0 to 3 | 1.2 (0.8) | 1.1 (0.6) | 1.4 (0.6) | 1.5 (0.7) | 0.7 (0.6) | 0.5 (0.5) |
DAS, 0 to 7 | 3.9 (1.2) | 3.9 (1.1) | 4.9 (1.2) | 3.6 (1.7) | 3.7 (1.2) | 3.0 (1.1) |
Ongoing MTX, yes, % | ---- | 100% | 76% | 56% | 100% | ---- |
MTX mg/week, mean | ---- | 17.2 | 15.6 | 14.7 | 16.4 | ---- |
Ongoing prednisolone, yes, % | 55.2% | 65.4% | 70.0% | 53.3% | 31.3% | 6.2% |
Prednisolone, mg/week, mean | 30.9 | 35.4 | 32.7 | 27.5 | 14.0% | 2.2 |
CRP mg/L, mean | 15.8 | 6.4 | 9.7 | 3.9 | 8.9 | 7.7 |
TJC28, mean (range) | 3.5 (0 to 23) | 4.7 (0 to 19) | 8.2 (0 to 20) | 7.6 (0 to 28) | 2.8 (0 to 12) | 1.9 (0 to 18) |
SJC, mean (range) | 3.4 (0 to 15) | 3.9 (0 to 13) | 4.8 (0 to 12) | 5.1 (0 to 25) | 2.0 (0 to 11) | 0.4 (0 to 5) |
RF-positive, % | 93% | 89% | 88% | 81% | 78% | NA |
Anti-CCP-positive, % | 86% | 92% | 82% | 63% | 75% | NA |
Smoker, % | 14% | 31% | 19% | 14% | 19% | 12% |
IgG at vaccination, g/L, mean (SD) | 8.2 (2.9) | 8.0 (2) | 9.1 (1.9) | 8.7 (2.6) | 9.7 (2.5) | 9.9 (2.1) |
IgM at vaccination, g/L, mean (SD) | 0.8 (0.7) | 0.9 (0.5) | 1.3 (0.7) | 1.1 (0.5) | 1.1 (0.6) | 1.0 (0.6) |
IgA at vaccination, g/L, mean (SD) | 2.3 (1.3) | 2.4 (0.9) | 2.9 (1.3) | 2.5 (0.9) | 2.5 (1.1) | 2.5 (1.1) |
Pneumococcal vaccine previously, % | 24.1% | 23.1% | 11.8% | 6.3% | 10.6% | 1.2% |
Last biologic treatment before vaccination, days, mean (range) | 71 (0 to 501) | 102 (0 to 894) | 8 (0 to 26) | 7 (0 to 34) | NA | NA |
Prevaccination antibody levels for 6B, mg/L, GML (95% CI) | 0.3 (0.2-0.6) | 0.4 (0.2, 0.8) | 0.6 (0.3, 1.4) | 0.4 (1.0, 1) | 2.0 (1.4, 2.8) | 2.9 (2.1, 4.0) |
Postvaccination antibody levels for 6B, mg/L, GML (95% CI) | 0.4 (0.2-0.8) | 0.4 (0.2, 0.8) | 1.1 (0.4, 2.7) | 1.7 (0.5, 5.8) | 3.5 (2.5, 4.9) | 9.5 (6.7, 13.6) |
Prevaccination antibody levels for 23F, mg/L, GML (95% CI) | 0.2 (0.1, 0.4) | 0.3 (0.1, 0.5) | 0.4 (0.2, 0.9) | 0.2 (0.1, 0.5) | 0.7 (0.5, 1.1) | 0.97 (0.7, 1.4) |
Postvaccination antibody levels for 23F, mg/L, GML (95% CI) | 0.3 (0.2, 0.6) | 0.4 (0.2, 0.8) | 1.1 (0.6, 2.3) | 2.2 (0.9-5.3) | 1.9 (1.4, 2.6) | 6.4 (4.5, 9.1) |